

Mechanism-guided novel therapies for treating systemic lupus erythematosus and other auto-inflammatory diseases

Prof. Sylviane Muller

CNRS-University of Strasbourg Unit Biotechnology and cell signaling,
University of Strasbourg Institute for Advanced Study (USIAS)/ Chair Therapeutic Immunology,
Strasbourg Drug Discovery and Development Institute (IMS)
Strasbourg, France

Nowadays, pharmacologic treatments of inflammatory and autoimmune diseases are largely palliative rather than curative. They result in non-specific immunosuppression, which can be associated with disruption of natural and induced immunity with significant, sometimes dramatic, adverse effects. Among the novel strategies that are under development, tools that target specific molecular pathways and cells, and more precisely modulate the immune system to restore normal tolerance mechanisms, are central. In these approaches, peptides represent a class of therapeutic drugs that display many physicochemical advantages in terms of stability, toxicity, absence of immunogenicity and unwanted side effects. Among peptide therapeutics of interest, the phosphopeptide P140 is very promising for treating patients with systemic lupus, and probably more largely patients with chronic inflammatory diseases. This peptide displays very favourable properties in terms of ADME (absorption, distribution, metabolism, and excretion). P140/Lupuzor is currently evaluated in phase III-clinical studies worldwide. This peptide targets key elements of endo-lysosomal autophagy, which is hyperactivated in lupus. Promising data have also been obtained in animal models mimicking Crohn's disease, Sjögren's syndrome, periodontitis, a rare neurological autoimmune disease (chronic inflammatory demyelinating polyneuropathy) and asthma. After the era of drugs classified as "disease-modifying" therapeutics, a new type of safe "mechanism-guided" therapies are beginning to emerge for treating inflammatory diseases.

- Bonam, S.R, Wang, F. & Muller, S. (2019) Lysosomes as a therapeutic target. *Nat. Rev. Drug Discov.*18:923-948.
- Wang, F., Tasset, I., Cuervo, A.M. & Muller, S. (2020) In vivo remodelling of altered autophagy-lysosomal pathway by a phosphopeptide in lupus. *Cells* 9:2328
- Schall, N., Talamini, L., Wilhelm, M., Jouvin-Marche, E. & Muller, S. (2022) P140 peptide leads to clearance of autoreactive lymphocytes and normalizes immune response in lupus-prone mice. *Front. Immunol.* 13,904669